Epiblox

Epiblox is tackling the most challenging forms of epilepsy, where existing treatments fail. Their primary focus is a rare and severe childhood epilepsy caused by KCNT1 gene mutations, leading to over 50 seizures daily despite multiple medications. Their lead drug candidate – a repurposed, well-characterized molecule – directly targets the underlying disease mechanism, aiming to reduce seizures, prevent developmental delays, and improve survival in affected children. 

With Orphan Drug and Rare Pediatric Disease designations from the US FDA, this therapy holds both life-changing potential and strong commercial viability.

Seeking: Funding to advance our lead candidate into clinical development. 

Interested in connecting? Ask the ON team via ON@csiro.au to facilitate a connection with us.

Meet the team